Surgery for Intrahepatic Cholangiocarcinoma with Lymph Node Dissection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of extended lymphadenectomy during the surgical resection of intrahepatic cholangiocarcinoma (ICC). The study aims to standardize the extent of lymph node dissection to improve the accuracy of staging and prognosis for patients with ICC. By comparing outcomes between standard and extended lymph node dissection, researchers hope to determine if a more extensive approach can enhance survival rates while managing complication risks. The trial includes patients aged 18 to 80 with resectable ICC and no significant lymph node metastasis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients \>18 years of age and ≤80 years of age;
* Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable;
* No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy
* Liver function Child-Turcotte-Pugh score A-B grade;
* Residual liver volume \>30%; can tolerate radical hepatectomy
* The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan;
* Sign the written informed consent form prior to the test screening.

Exclusion Criteria:

* The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma;
* The patient has a history of other malignant tumors;
* Liver function Child-Turcotte-Pugh score C;
* The investigator determined that it was not suitable for the study.

Where it's running

• The Johns Hopkins Hospital
  Baltimore, Maryland, United States Recruiting
• China-Japan Friendship Hospital
  Beijing, Beijing Municipality, China Recruiting
• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting
• Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
  Guangzhou, Guangdong, China Recruiting
• Hunan Provincial People's Hospital
  Changsha, Hunan, China Recruiting
• The Affiliated Hospital of Inner Mongolia Medical University
  Hohhot, Inner Mongolia, China Recruiting

Study contacts

• Study coordinator: Jiang-Tao LI, PHD;MD
• Email: zjulijiangtao@163.com
• Phone: 86-15906686716

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma

  This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07766187

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• Chidamide plus chemotherapy and immunotherapy for advanced intrahepatic cholangiocarcinoma

  This trial will test whether adding the oral drug chidamide to gemcitabine/cisplatin and an immune checkpoint inhibitor helps people with unresectable or metastatic intrahepatic cholangiocarcinoma who have not had prior systemic therapy.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07570849

• VG2025 in intrahepatic cholangiocarcinoma

  VG2025 is tested in adults with advanced intrahepatic cholangiocarcinoma to see if it can help control tumors and be safe.

  Recruiting Phase 2 Virogin Biotech Ltd. · Hangzhou, Zhejiang · NCT07522476

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.